{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:22:52Z","timestamp":1767147772200,"version":"build-2238731810"},"update-to":[{"DOI":"10.1016\/j.jinf.2022.11.013","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:00:00Z","timestamp":1668902400000}}],"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jinf.2022.11.013","type":"journal-article","created":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T01:19:19Z","timestamp":1668907159000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["WITHDRAWN: Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis"],"prefix":"10.1016","author":[{"given":"Xia","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laozei","family":"Sima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.jinf.2022.11.013_bib0001","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jinf.2022.11.013_bib0002","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1038\/s41375-021-01302-5","article-title":"COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey","volume":"35","author":"Ljungman","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.jinf.2022.11.013_bib0003","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.17704","article-title":"COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies","volume":"195","author":"Passamonti","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jinf.2022.11.013_bib0004","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1038\/s41409-020-0919-0","article-title":"The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T- cell therapy","volume":"55","author":"Ljungman","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"14","key":"10.1016\/j.jinf.2022.11.013_bib0005","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJMc2112981","article-title":"Resurgence of SARS-CoV-2 Infection in a highly vaccinated health system workforce","volume":"385","author":"Keehner","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jinf.2022.11.013_bib0006","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-CoV-2 Vaccines","volume":"325","author":"Creech","year":"2021","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jinf.2022.11.013_bib0007","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2022.11.013_bib0008","unstructured":"https:\/\/www.hematology.org\/covid-19\/ash-astct-covid-19-vaccination-for-hct-and-car-t-cell-recipients, Accessed 8 November 2021."},{"key":"10.1016\/j.jinf.2022.11.013_bib0009","unstructured":"https:\/\/www.ebmt.org\/covid-19-and-bmt, Accessed 8 November 2021."},{"issue":"2","key":"10.1016\/j.jinf.2022.11.013_bib0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0011","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti- myeloma treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.jinf.2022.11.013_bib0012","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood.2021011904","article-title":"Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose","volume":"137","author":"Terpos","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0013","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0014","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ccell.2021.06.014","article-title":"Highly variable SARS- CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma","volume":"39","author":"van Oekelen","year":"2021","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.jinf.2022.11.013_bib0015","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1038\/s41375-021-01354-7","article-title":"Response to mRNA vaccination for COVID-19 among patients with multiple myeloma","volume":"35","author":"Stampfer","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jinf.2022.11.013_bib0016","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jinf.2022.11.013_bib0017","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy - a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jinf.2022.11.013_bib0018","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-021-01130-1","article-title":"Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jinf.2022.11.013_bib0019","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13045-021-01090-6","article-title":"Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution","volume":"14","author":"Pimpinelli","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jinf.2022.11.013_bib0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jinf.2022.11.013_bib0021","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0022","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0023","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak immunogenicity of SARS- CoV-2 vaccine in patients with hematologic malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0024","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2352-3026(21)00199-X","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma","volume":"8","author":"Lim","year":"2021","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0025","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1097\/HS9.0000000000000614","article-title":"Antibody response after initial vaccination for SARS-CoV-2 in patients with amyloidosis","volume":"5","author":"Kastritis","year":"2021","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0026","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jgo.2021.06.002","article-title":"Serological response to COVID-19 vaccination in patients with cancer older than 80 years","volume":"12","author":"Iacono","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"10.1016\/j.jinf.2022.11.013_bib0027","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.jinf.2022.11.013_bib0028","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3324\/haematol.2021.279216","article-title":"Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies","volume":"107","author":"Gurion","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0029","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.jinf.2022.11.013_bib0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jinf.2022.11.013_bib0031","first-page":"1","article-title":"Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine","author":"Gavriatopoulou","year":"2021","journal-title":"Clin Exp Med"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0032","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.jinf.2022.11.013_bib0033","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.jtct.2021.07.011","article-title":"Serologic responses following a single dose of SARS-Cov-2 vaccination in allogeneic stem cell transplantation recipients","volume":"27","author":"Easdale","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jinf.2022.11.013_bib0034","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00277-021-04613-w","article-title":"Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis","volume":"101","author":"Caocci","year":"2022","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.jinf.2022.11.013_bib0035","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(21)00110-1","article-title":"Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma","volume":"8","author":"Bird","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.jinf.2022.11.013_bib0036","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jinf.2022.11.013_bib0037","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.17743","article-title":"Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients","volume":"195","author":"Benda","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.jinf.2022.11.013_bib0038","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jtct.2021.07.008","article-title":"Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients","volume":"27","author":"Ali","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.jinf.2022.11.013_bib0039","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.jinf.2022.11.013_bib0040","doi-asserted-by":"crossref","first-page":"ofab353","DOI":"10.1093\/ofid\/ofab353","article-title":"Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era","volume":"8","author":"Agha","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"14","key":"10.1016\/j.jinf.2022.11.013_bib0041","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021012769","article-title":"Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy","volume":"138","author":"Dhakal","year":"2021","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jinf.2022.11.013_bib0042","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jinf.2022.11.013_bib0043","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjh.17608","article-title":"Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma","volume":"195","author":"Avivi","year":"2021","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.jinf.2022.11.013_bib0044","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.3390\/cancers13153800","article-title":"Post-vaccination anti-SARS-CoV-2-antibody response in patients with multiple myeloma correlates with low CD19+ B-lymphocyte count and anti- CD38 treatment","volume":"13","author":"Ghandili","year":"2021","journal-title":"Cancers. (Basel)"},{"issue":"10297","key":"10.1016\/j.jinf.2022.11.013_bib0045","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(21)01594-4","article-title":"Antibody response after second BNT162b2 dose in allogeneic HSCT recipients","volume":"398","author":"Redjoul","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jinf.2022.11.013_bib0046","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2643-3230.BCD-21-0139","article-title":"Disease and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies","volume":"2","author":"Chung","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"6","key":"10.1016\/j.jinf.2022.11.013_bib0047","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/2643-3230.BCD-21-0142","article-title":"Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T cell therapy","volume":"2","author":"Tamari","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"10.1016\/j.jinf.2022.11.013_bib0048","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hon.2916","article-title":"COVID-19 vaccination: evaluation of risk for protection failure in chronic lymphocytic leukemia patients","volume":"39","author":"Del Poeta","year":"2021","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1016\/j.jinf.2022.11.013_bib0049","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1002\/ajh.26322","article-title":"Serologic response to mRNA COVID-19 vaccination in lymphoma patients","volume":"96","author":"Jurgens","year":"2021","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.jinf.2022.11.013_bib0050","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.ccell.2021.08.001","article-title":"Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer","volume":"39","author":"Mairhofer","year":"2021","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.jinf.2022.11.013_bib0051","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry","year":"2021","journal-title":"Blood Adv"},{"issue":"17","key":"10.1016\/j.jinf.2022.11.013_bib0052","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.3390\/cancers13174480","article-title":"Poor neutralizing antibody responses in 132 patients with CLL, NHL and HL after vaccination against SARS-CoV-2: a prospective study","volume":"13","author":"Terpos","year":"2021","journal-title":"Cancers. (Basel)"},{"issue":"11","key":"10.1016\/j.jinf.2022.11.013_bib0053","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1001\/jamaoncol.2021.4381","article-title":"Antibody response to COVID-19 vaccination in adults with hematologic malignant disease","volume":"7","author":"Ollila","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.jinf.2022.11.013_bib0054","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1038\/s41375-021-01300-7","article-title":"Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms","volume":"35","author":"Harrington","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jinf.2022.11.013_bib0055","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.17568","article-title":"Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia","volume":"194","author":"Harrington","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jinf.2022.11.013_bib0056","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.17818","article-title":"Safety and antibody response after one and\/or two doses of BNT162b2 Anti- SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy","volume":"196","author":"Gastinne","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jinf.2022.11.013_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100274","article-title":"Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment","volume":"6","author":"Peeters","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.jinf.2022.11.013_bib0058","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/bjh.17821","article-title":"The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2","volume":"196","author":"Marchesi","year":"2022","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jinf.2022.11.013_bib0059","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.26344","article-title":"Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant","volume":"4","author":"Le Bourgeois","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jinf.2022.11.013_bib0060","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jinf.2022.11.013_bib0061","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jinf.2022.11.013_bib0062","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjh.17877","article-title":"T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies","volume":"196","author":"Marasco","year":"2022","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jinf.2022.11.013_bib0063","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1001\/jamaoncol.2016.2437","article-title":"Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"2","author":"Sun","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jinf.2022.11.013_bib0064","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood.2020008758","article-title":"Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines","volume":"137","author":"Pleyer","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jinf.2022.11.013_bib0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.599098","article-title":"Actors on the scene: immune cells in the myeloma niche","volume":"10","author":"Leone","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jinf.2022.11.013_bib0066","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41375-020-01016-0","article-title":"Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.jinf.2022.11.013_bib0067","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody Isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jinf.2022.11.013_bib0068","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.3324\/haematol.2019.231860","article-title":"Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients","volume":"105","author":"Frerichs","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jinf.2022.11.013_bib0069","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am J Hematol"},{"issue":"17","key":"10.1016\/j.jinf.2022.11.013_bib0070","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jinf.2022.11.013_bib0071","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"}],"updated-by":[{"DOI":"10.1016\/j.jinf.2022.11.013","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,11,20]],"date-time":"2022-11-20T00:00:00Z","timestamp":1668902400000}}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445322006740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445322006740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T20:48:33Z","timestamp":1759006113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445322006740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":71,"alternative-id":["S0163445322006740"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2022.11.013","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WITHDRAWN: Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2022.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}